134 related articles for article (PubMed ID: 32393999)
1. Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients.
Waki K; Yokomizo K; Kawano K; Tsuda N; Komatsu N; Yamada A
Cancer Immunol Immunother; 2020 Oct; 69(10):2001-2007. PubMed ID: 32393999
[TBL] [Abstract][Full Text] [Related]
2. Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer.
Waki K; Yokomizo K; Yoshiyama K; Takamori S; Komatsu N; Yamada A
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):176-182. PubMed ID: 33541161
[TBL] [Abstract][Full Text] [Related]
3. CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients.
Waki K; Kawano K; Tsuda N; Komatsu N; Yamada A
Cancer Sci; 2020 Apr; 111(4):1124-1131. PubMed ID: 32058620
[TBL] [Abstract][Full Text] [Related]
4. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; ; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C
Gynecol Oncol; 2021 Sep; 162(3):720-727. PubMed ID: 34454680
[TBL] [Abstract][Full Text] [Related]
5. Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer.
Kitahara M; Hazama S; Tsunedomi R; Takenouchi H; Kanekiyo S; Inoue Y; Nakajima M; Tomochika S; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yamamoto S; Yoshino S; Nagano H
Cancer Sci; 2016 Dec; 107(12):1825-1829. PubMed ID: 27663862
[TBL] [Abstract][Full Text] [Related]
6. Integrity of plasma cell-free DNA as a prognostic factor for vaccine therapy in patients with endometrial cancer.
Waki K; Yokomizo K; Kawano K; Tsuda N; Komatsu N; Yamada A
Mol Clin Oncol; 2021 Feb; 14(2):29. PubMed ID: 33414910
[TBL] [Abstract][Full Text] [Related]
7. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
[TBL] [Abstract][Full Text] [Related]
8. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
9. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Rusan M; Andersen RF; Jakobsen A; Steffensen KD
Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical applications of circulating cell-free DNA in ovarian cancer patients.
Barbosa A; Peixoto A; Pinto P; Pinheiro M; Teixeira MR
Expert Rev Mol Med; 2018 Dec; 20():e6. PubMed ID: 30558693
[TBL] [Abstract][Full Text] [Related]
11. Quantification of circulating plasma cell free DNA fragments in patients with oral cancer and precancer.
Desai A; Kallianpur S; Mani A; Tijare MS; Khan S; Jain M; Mathur V; Ahuja R; Saxena V
Gulf J Oncolog; 2018 May; 1(27):11-17. PubMed ID: 30145546
[TBL] [Abstract][Full Text] [Related]
12. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
[TBL] [Abstract][Full Text] [Related]
13. Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer.
Waki K; Kawano K; Tsuda N; Ushijima K; Itoh K; Yamada A
J Immunol Res; 2017; 2017():1423683. PubMed ID: 28536706
[TBL] [Abstract][Full Text] [Related]
14. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Brown TA; Byrd K; Vreeland TJ; Clifton GT; Jackson DO; Hale DF; Herbert GS; Myers JW; Greene JM; Berry JS; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwel GL; Peoples GE
Cancer Med; 2019 Aug; 8(10):4678-4687. PubMed ID: 31274231
[TBL] [Abstract][Full Text] [Related]
15. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
Kawano K; Tsuda N; Waki K; Matsueda S; Hata Y; Ushijima K; Itoh K; Yamada A; Kamura T
Cancer Sci; 2015 Sep; 106(9):1111-7. PubMed ID: 26122553
[TBL] [Abstract][Full Text] [Related]
16. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.
Blumendeller C; Boehme J; Frick M; Schulze M; Rinckleb A; Kyzirakos C; Kayser S; Kopp M; Kelkenberg S; Pieper N; Bartsch O; Hadaschick D; Battke F; Stenzl A; Biskup S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431630
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
[TBL] [Abstract][Full Text] [Related]
19. Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer.
Günel T; Gumusoglu E; Dogan B; Ertem FB; Hosseini MK; Cevik N; Senol T; Topuz S; Aydinli K
Arch Gynecol Obstet; 2018 Dec; 298(6):1173-1180. PubMed ID: 30264202
[TBL] [Abstract][Full Text] [Related]
20. Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.
Yu Z; Qin S; Wang H
J Obstet Gynaecol Res; 2019 Nov; 45(11):2237-2242. PubMed ID: 31502389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
